By applying the expertise, best practice, and emerging technologies of the logistics industry, biotech not only prevents the missteps that can destroy its products, it can also capitalise on opportunities to get to new markets faster, safer and more cost effectively.
A SARS-CoV-2-specific T cell isolation method
Sponsored PublicationsThe COVID-19 pandemic created exceptional circumstances for virologists. To speed up the process from initial basic experiments to the final clinical application, appropriate reagents are required. Isolation of SARS-CoV-2-specific T cells via the MHC Streptamer® approach yields label-free, fully functional cells, making this method a valuable tool for high quality research.
BIAL with new R&D General Manager
AppointmentsBIAL, a public limited company under Portuguese law with head office in Coronado, Portugal, appointed Joerg Holenz as R&D General Manager and as a member of the Board of Directors.
EU orders up Valneva’s inactivated Covid-19 vaccine
Latest NewsThe EU has secured 60 million doses of Valneva’s potential Covid-19 vaccine VLA2001. When approvied, it would be the first inactivated vaccine on the EU market.
Managing risks and finding opportunities through logistics
Sponsored PublicationsBy applying the expertise, best practice, and emerging technologies of the logistics industry, biotech not only prevents the missteps that can destroy its products, it can also capitalise on opportunities to get to new markets faster, safer and more cost effectively.
LSP and EQT merge to create top-10 investment firm
Latest NewsLife Sciences investor LSP is set to being acquired by Europe’s largest equity specialist EQT AB.
Stock market boom: Two biotechs go public
Latest NewsTwo European oncology biopharma companies have made the leap onto the stock market: French MaaT Pharma went public on Euronext Paris, while Danish IO Biotech chose Nasdaq Global Market for its IPO.
LSP raises a whopping €850m for the European life sciences
Latest NewsEuropean life science investor LSP has raised €850m for its 7th generation flagship fund LSP 7.
Mogrify strengthens leadership team
AppointmentsCambridge-based Mogrify Limited announced the appointment of Tom Graney CFA as Non-Executive Director, Audit Chair and Capital Markets Advisor.
Novartis inks US-$1.3bn deal with Dunad Therapeutics
Latest NewsDunad Therapeutics Ltd had entered into a $1.3bn option deal with Swiss pharma major Novartis AG to develop targeted protein degrader therapies.
Pioneers of Omics Virtual Event Series
Sponsored PublicationsNew, ongoing, free event series about researchers work in the exciting fields of multi-omics. Each session will take a particular field of omics research and showcase some of the exciting research being undertaken from around the world.